Stocks · News reference

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Sep 10, 2026, 1:08 PMBenzinga Newsdesk

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 17, 2026, 1:43 PMBenzinga Insights
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
ONC
BenzingaSep 1, 2026, 8:57 AMNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
ALC BBIO LLY NVO ONC
BenzingaAug 31, 2026, 7:44 PMBenzinga Newsdesk
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
BBIO ONC SPY TEVA